Strategic approaches to developing drug treatments for ALS

被引：22

作者：

Vincent, Andrea M. ^{[1
]}

Sakowski, Stacey A. ^{[1
]}

Schuyler, Adam ^{[1
]}

Feldman, Eva L. ^{[1
]}

机构：

[1] Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA

来源：

DRUG DISCOVERY TODAY | 2008年 / 13卷 / 1-2期

关键词：

D O I：

10.1016/j.drudis.2007.10.011

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Significant progress in understanding the cellular mechanisms of motor neuron degeneration in amyotrophic lateral sclerosis (ALS) has not been matched with the development of therapeutic strategies to prevent disease progression. The multiple potential causes and relative rarity of the disease are two significant factors that make drug development and assessment in clinical trials extremely difficult. We review recent progress in promoting therapeutics into clinical trials and highlight the value of moderate throughput screening for the acceleration and improvement of drug design.

引用

页码：67 / 72

页数：6

共 50 条

[31] DEVELOPING STRATEGIC LEARNERS
不详
[J]. JOURNAL OF READING, 1989, 33 (01): : 61 - 63
[32] Developing a strategic plan
Kane, M
Davidhizar, L
Uitermarkt, C
[J]. COLLECTION OF PAPERS ON SELF-STUDY AND INSTITUTIONAL IMPROVEMENT 1996, 1996, : 262 - 263
[33] Developing and applying computational approaches in early-stage drug discovery
Balius, Trent
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
[34] Migration of health-care workers from developing countries: strategic approaches to its management
Stilwell, B
Diallo, K
Zurn, P
Vujicic, M
Adams, O
Dal Poz, M
[J]. BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2004, 82 (08) : 595 - 600
[35] Evaluation of Strategic Approaches Against Drug Abuse in Education Institutions According to Stakeholders' Opinions
Dincyurek, S.
Dagli, G.
Altinay, Z.
[J]. PEGEM EGITIM VE OGRETIM DERGISI, 2024, 14 (04): : 215 - 222
[36] Developing Novel Treatments for Psychiatric Illnesses: Can Drug Development Tool Qualification Advance CNS Drug Development?
Brady, Linda
Davis, Michael
Pandina, Gahan
Cannon, Tyrone
Kolb, Hartmuth
McPartland, James
Leptak, Chris
Horner, Michelle
Reasner, David
Lisanby, Sarah
Graham, Danielle
Dage, Jeffrey
Berman, Steven
[J]. NEUROPSYCHOPHARMACOLOGY, 2021, 46 (SUPPL 1) : 41 - 42
[37] Mosaic chemotherapy strategies for developing ALS/MND therapeutic approaches: Beta-2 adrenergic agonists
Brooks, BR
Juhasz-Poscine, K
Waclawik, A
Sanjak, M
Belden, D
Roelke, K
Parnell, J
Weasler, C
[J]. AMYOTROPHIC LATERAL SCLEROSIS, 2000, 1 : 45 - 53
[38] Candidate drug for ALS
Pamela Feliciano
[J]. Nature Genetics, 2013, 45 (7) : 722 - 722
[39] Editorial: Developing Successful Neuroprotective Treatments for TBI: Translational Approaches, Novel Directions, Opportunities and Challenges
Mondello, Stefania
Hasan, Anwarul
Shear, Deborah A.
[J]. FRONTIERS IN NEUROLOGY, 2019, 10
[40] New strategic plan takes the ALS into the future
Kirz, J.
Chemla, D. S.
Feinberg, B.
Hussain, Z.
Krebs, G. F.
Padmore, H. A.
Robin, D. S.
Robinson, A. L.
Smith, N. V.
Warwick, T.
[J]. SYNCHROTRON RADIATION INSTRUMENTATION, PTS 1 AND 2, 2007, 879 : 159 - +

← 1 2 3 4 5 →